TG Therapeutics, Inc. TGTX
NASDAQ · United States · Health Technology
$54.39-1.39 (-2.49%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling.
TG Therapeutics (TGTX) steps into the spotlight ahead of its H.C. Wainwright conference appearance on September 14, drawing fresh attention after the stock recently bounced off its 50-day moving average. Across the past few months, TG Therapeutics has leaned into stronger momentum, with a 30-day share price return of 12.36% and a year-to-date share price return of 92.86%. The one-year total shareholder return of 73.17% and roughly 5x three-year total shareholder return suggest earlier buyers...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.